**Patient Discharge Summary**

**Patient Information:**

* Name: Jane Doe
* Date of Birth: March 12, 1975
* Date of Admission: March 22, 2023
* Date of Discharge: March 28, 2023

**Chief Complaint:**

Jane Doe, a 48-year-old female, was admitted to the endocrinology unit on March 22, 2023, with symptoms of increased thirst and urination, blurred vision, and fatigue.

**Medical History:**

* No significant medical history prior to admission.

**Physical Examination:**

* Vital signs: Blood pressure 140/90 mmHg, pulse 72 beats per minute, temperature 98.6°F (37°C), and oxygen saturation 98% on room air.
* Height: 5 feet 8 inches (173 cm); Weight: 180 pounds (82 kg)
* General: Well-nourished, well-developed female with no acute distress.
* Head, Eyes, Ears, Nose, and Throat (HEENT): Normal.
* Cardiovascular: Normal.
* Respiratory: Normal.
* Abdomen: Soft, non-tender.
* Neurological: Normal.
* Skin: Normal.
* Extremities: Normal.

**Laboratory Results:**

* Fasting plasma glucose (FPG) level: 240 mg/dL (11.1 mmol/L) on March 23, 2023.
* Glycosylated hemoglobin (HbA1C) level: 9.5% on March 24, 2023.
* Urine testing for albuminuria: Normal.
* Serum creatinine and lipid profile: Normal.

**Diagnosis:**

* Type 2 diabetes, based on FPG level and HbA1C level.

**Treatment:**

* Diet: Individualized diet plan focusing on whole foods, high-quality carbohydrates, and accommodating comorbid conditions.
* Exercise: Recommended at least 150 minutes/week, with adjustments for hypoglycemia risk, including both aerobic and resistance exercise.
* Medications:
	+ Metformin 500 mg twice daily, initiated on March 24, 2023.
	+ Semaglutide 2.4 mg subcutaneously once weekly, initiated on March 25, 2023.
* Patient education:
	+ Causes of diabetes, symptoms and signs of hypoglycemia, hyperglycemia, and diabetic complications.
	+ Adjusting insulin doses based on blood glucose levels and carbohydrate intake.
	+ Importance of regular professional podiatric care and vaccinations.

**Plan:**

* Continue metformin 500 mg twice daily and semaglutide 2.4 mg subcutaneously once weekly.
* Monitor blood glucose levels regularly and adjust insulin doses as necessary.
* Follow-up appointment with the endocrinologist in two weeks to reassess blood glucose control and adjust therapy as needed.

**Special Instructions:**

* Monitor for signs of hypoglycemia and hyperglycemia, such as shakiness, dizziness, or blurred vision.
* Adjust insulin doses based on blood glucose levels and carbohydrate intake.
* Follow the individualized diet plan and engage in regular physical activity.
* Attend regular follow-up appointments with the endocrinologist.

**Discharge Medications:**

* Metformin 500 mg twice daily
* Semaglutide 2.4 mg subcutaneously once weekly

**Discharge Instructions:**

* Follow the prescribed diet plan and exercise regimen.
* Monitor blood glucose levels regularly and adjust insulin doses as necessary.
* Attend regular follow-up appointments with the endocrinologist.
* Be aware of signs of hypoglycemia and hyperglycemia and seek medical attention if necessary.

**Follow-up Appointments:**

* Follow-up appointment with the endocrinologist in two weeks to reassess blood glucose control and adjust therapy as needed.

**Patient Education:**

* Patient education on the causes of diabetes, symptoms and signs of hypoglycemia, hyperglycemia, and diabetic complications.
* Patient education on adjusting insulin doses based on blood glucose levels and carbohydrate intake.
* Patient education on the importance of regular professional podiatric care and vaccinations.

**Additional Notes:**

* Patient was educated on the importance of regular monitoring of blood glucose levels and adjusting insulin doses as necessary.
* Patient was educated on the importance of regular professional podiatric care and vaccinations.
* Patient was educated on the importance of following the individualized diet plan and engaging in regular physical activity.

**Discharge Summary:**

Jane Doe was discharged from the hospital on March 28, 2023, with a diagnosis of type 2 diabetes. She was started on metformin 500 mg twice daily and semaglutide 2.4 mg subcutaneously once weekly. She was educated on the causes of diabetes, symptoms and signs of hypoglycemia, hyperglycemia, and diabetic complications, and on adjusting insulin doses based on blood glucose levels and carbohydrate intake. She was also educated on the importance of regular professional podiatric care and vaccinations. The patient was instructed to follow up with the endocrinologist in two weeks to reassess blood glucose control and adjust therapy as needed.